Search research articles
Contact Us
Filters
Showing results (411-420 of 471) with videos related to
Page
of 48
Sort By:
Transplantation and Cellular Therapy
|
August 8, 2022
Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy
Mohammad Ebraheem, Shaji K Kumar, Angela Dispenzieri, et al.
Annals of Hematology
|
April 4, 2018
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia
Jonas Paludo, Jithma P Abeykoon, Amanda Shreders, et al.
Blood
|
October 6, 2016
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib
Shaji K Kumar, Betsy R LaPlant, Craig B Reeder, et al.
Leukemia
|
August 28, 2024
The clinical impact of acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia: an underrecognized source of major bleeding events
Karan L Chohan, Rajiv K Pruthi, Saurabh Zanwar, et al.
Mayo Clinic Proceedings
|
August 12, 2006
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma
Martha Q Lacy, Angela Dispenzieri, Morie A Gertz, et al.
Blood Advances
|
June 23, 2022
Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis
Eli Muchtar, Morie A Gertz, Betsy R LaPlant, et al.
American Journal of Hematology
|
July 4, 2020
Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation
Cihan Heybeli, Meera Sridharan, Hassan B Alkhateeb, et al.
Mayo Clinic Proceedings
|
August 8, 2015
Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement
Angela Dispenzieri, Francis Buadi, Shaji K Kumar, et al.
Circulation. Cardiovascular Imaging
|
May 13, 2018
Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis
Paolo Milani, Angela Dispenzieri, Christopher G Scott, et al.
American Journal of Hematology
|
June 2, 2017
The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma
Toshi Ghosh, Wilson I Gonsalves, Dragan Jevremovic, et al.
Page
of 48
Search research articles
Search
Showing results (411-420 of 471) with videos related to
Sort By:
Page
of 48
Transplantation and Cellular Therapy
|
August 8, 2022
Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy
Mohammad Ebraheem, Shaji K Kumar, Angela Dispenzieri, et al.
Annals of Hematology
|
April 4, 2018
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia
Jonas Paludo, Jithma P Abeykoon, Amanda Shreders, et al.
Blood
|
October 6, 2016
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib
Shaji K Kumar, Betsy R LaPlant, Craig B Reeder, et al.
Leukemia
|
August 28, 2024
The clinical impact of acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia: an underrecognized source of major bleeding events
Karan L Chohan, Rajiv K Pruthi, Saurabh Zanwar, et al.
Mayo Clinic Proceedings
|
August 12, 2006
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma
Martha Q Lacy, Angela Dispenzieri, Morie A Gertz, et al.
Blood Advances
|
June 23, 2022
Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis
Eli Muchtar, Morie A Gertz, Betsy R LaPlant, et al.
American Journal of Hematology
|
July 4, 2020
Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation
Cihan Heybeli, Meera Sridharan, Hassan B Alkhateeb, et al.
Mayo Clinic Proceedings
|
August 8, 2015
Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement
Angela Dispenzieri, Francis Buadi, Shaji K Kumar, et al.
Circulation. Cardiovascular Imaging
|
May 13, 2018
Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis
Paolo Milani, Angela Dispenzieri, Christopher G Scott, et al.
American Journal of Hematology
|
June 2, 2017
The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma
Toshi Ghosh, Wilson I Gonsalves, Dragan Jevremovic, et al.
Page
of 48